A5015206910- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Single-cell and spatial transcriptomics
- Chronic Myeloid Leukemia Treatments
- Veterinary Oncology Research
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations
- Glioma Diagnosis and Treatment
- Molecular Biology Techniques and Applications
- Pancreatic and Hepatic Oncology Research
- Epigenetics and DNA Methylation
- Microbial infections and disease research
- Colorectal Cancer Treatments and Studies
- Infectious Diseases and Mycology
- Prenatal Screening and Diagnostics
- Gastric Cancer Management and Outcomes
- Ocular Oncology and Treatments
- Renal and related cancers
- Neuroblastoma Research and Treatments
- Prostate Cancer Treatment and Research
- Virus-based gene therapy research
- Cancer Cells and Metastasis
- Ferroptosis and cancer prognosis
Memorial Sloan Kettering Cancer Center
2016-2025
Cornell University
2020-2023
Weill Cornell Medicine
2020-2023
Kettering University
2018-2022
Molecular Oncology (United States)
2016-2021
University of Cambridge
2013-2018
Cancer Research UK Cambridge Center
2018
Cancer Research UK
2012-2018
Addenbrooke's Hospital
2013
National Health Service
2013
The management of metastatic breast cancer requires monitoring the tumor burden to determine response treatment, and improved biomarkers are needed. Biomarkers such as antigen 15-3 (CA 15-3) circulating cells have been widely studied. However, cell-free DNA carrying tumor-specific alterations (circulating DNA) has not extensively investigated or compared with other in cancer.
Sizable genomic regions were screened and low-frequency mutations identified in circulating DNA of cancer patients using tagged-amplicon deep sequencing (TAm-Seq).
Abstract Circulating tumour DNA analysis can be used to track burden and analyse cancer genomes non-invasively but the extent which it represents metastatic heterogeneity is unknown. Here we follow a patient with ER-positive HER2-positive breast receiving two lines of targeted therapy over 3 years. We characterize genomic architecture infer clonal evolution in eight biopsies nine plasma samples collected 1,193 days clinical follow-up using exome amplicon sequencing. Mutation levels reflect...
Abstract Tumour heterogeneity in primary prostate cancer is a well-established phenomenon. However, how the subclonal diversity of tumours changes during metastasis and progression to lethality poorly understood. Here we reveal precise direction metastatic spread across four lethal patients using whole-genome ultra-deep targeted sequencing longitudinally collected tumours. We find one case surgical bed causing local recurrence, another cross-metastatic site seeding combining with dynamic...
Circulating cell-free DNA from blood plasma of cancer patients can be used to non-invasively interrogate somatic tumor alterations. Here we develop MSK-ACCESS (Memorial Sloan Kettering - Analysis cfDNA Examine Somatic Status), an NGS assay for detection very low frequency alterations in 129 genes. Analytical validation demonstrated 92% sensitivity de-novo mutation calling down 0.5% allele and 99% a priori profiling. To evaluate the performance MSK-ACCESS, report results 681 prospective...
The goal of cancer screening is to detect disease at an early stage when treatment may be more effective. Cancer in dogs has relied upon annual physical examinations and routine laboratory tests, which are largely inadequate for detecting preclinical disease. With the introduction non-invasive liquid biopsy detection methods, discussion shifting from how screen cancer. To address this question, we analyzed data 3,452 cancer-diagnosed determine age certain breeds weights typically diagnosed...
<h3>Importance</h3> The combination of erlotinib and bevacizumab as initial treatment epidermal growth factor receptor (<i>EGFR</i>[OMIM131550])–mutant lung cancers improves progression-free survival (PFS) compared with alone. Because osimertinib prolongs PFS erlotinib, this trial was designed to study the first-line treatment. <h3>Objectives</h3> To determine safety tolerability assess 12-month in patients metastatic<i>EGFR</i>-mutant cancers. <h3>Design, Setting, Particiants</h3> From...
Abstract Muscle Invasive Bladder Cancer (MIBC) has a poor prognosis. Whilst patients can achieve 6% improvement in overall survival with Neo-Adjuvant Chemotherapy (NAC), many do not respond. Body fluid mutant DNA (mutDNA) may allow non-invasive identification of treatment failure. We collected 248 liquid biopsy samples including plasma, cell pellet (UCP) and supernatant (USN) from spun urine, 17 undergoing NAC. assessed single nucleotide variants copy number alterations mutDNA using...
Diagnosing the site of origin for cancer is a pillar disease classification that has directed clinical care more than century. Even in an era precision oncologic practice, which treatment increasingly informed by presence or absence mutant genes responsible growth and progression, tumor remains critical factor biologic characteristics therapeutic sensitivity.To evaluate whether data derived from routine DNA sequencing tumors could complement conventional approaches to enable improved...
Circulating tumor DNA (ctDNA) offers new opportunities for noninvasive cancer management. Detecting ctDNA in plasma is challenging because it constitutes only a minor fraction of the total cell-free (cfDNA). Pre-analytical factors affect cfDNA levels contributed from leukocyte lysis, hence ability to detect low-frequency mutant alleles. This study investigates effects delay processing, storage temperatures, different blood collection tubes, centrifugation protocols, and sample shipment on...
The factors responsible for the low detection rate of cell-free tumor DNA (ctDNA) in plasma patients with glioblastoma (GBM) are currently unknown. In this study, we measured circulating nucleic acids patient-derived orthotopically implanted xenograft (PDOX) models GBM (
Research Article30 May 2018Open Access Transparent process Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies non-small cell lung cancer Dana Wai Yi Tsui orcid.org/0000-0002-0595-6664 Cancer UK Cambridge Institute, Li Ka Shing Centre, University Cambridge, Major Center - Search for more papers by this author Muhammed Murtaza Department Oncology, Alvin Seng Cheong Wong Haematology-Oncology, National Health System, Singapore, Singapore Oscar M Rueda...
6001 Background: SGCs are rare tumors with no approved therapy for metastatic disease. HER2 amplification occurs in 8% among all SGC histologies, and 25-33% of the aggressive salivary duct carcinoma (SDC) histologic subtype. We hypothesized that ado-trastuzumab emtansine, a targeted antibody drug conjugate, may be clinically active these patients. Methods: A cohort patients amplified were enrolled into multi-histology basket trial treated at 3.6mg/kg IV every 3 weeks. The primary endpoint...
Abstract Background Cell-free DNA (cfDNA) profiling is increasingly used to guide cancer care, yet mutations are not always identified. The ability detect somatic in plasma depends on both assay sensitivity and the fraction of circulating that tumor-derived (i.e., cfDNA tumor fraction). We hypothesized could inform interpretation negative results choice subsequent assays greater genomic breadth or depth. Methods Plasma samples collected from 118 metastatic patients were analyzed with...
Cancer is the leading cause of death in dogs, yet there are no established screening paradigms for early detection. Liquid biopsy methods that interrogate cancer-derived genomic alterations cell-free DNA blood being adopted multi-cancer detection human medicine and now available veterinary use. The CANcer Detection Dogs (CANDiD) study an international, multi-center clinical designed to validate performance a novel "liquid biopsy" test developed noninvasive characterization cancer dogs using...
Abstract Mutational signatures accumulate in somatic cells as an admixture of endogenous and exogenous processes that occur during individual’s lifetime. Since dividing release cell-free DNA (cfDNA) fragments into the circulation, we hypothesize plasma cfDNA might reflect mutational signatures. Point mutations whole genome sequencing (WGS) are challenging to identify through conventional mutation calling due low coverage mutant allele fractions. In this proof concept study WGS at 0.3–1.5x...
The enucleation rate for retinoblastoma has dropped from over 95% to under 10% in the past 10 years as a result of improvements therapy. This reduces access tumor tissue molecular profiling, especially unilateral retinoblastoma, and hinders confirmation somatic RB1 mutations necessary genetic counseling. Plasma cell-free DNA (cfDNA) provided platform noninvasive profiling cancer, but its applicability low burden not been shown. We analyzed cfDNA collected patients with available determine...